Zobrazeno 1 - 10
of 13
pro vyhledávání: '"L A, Miers"'
Publikováno v:
International Journal for Numerical Methods in Engineering. 76:1090-1107
A meshless procedure, based on boundary integral equations, is proposed to analyze elastoplastic problems. To cope with non-linear problems, the usual boundary element method introduces domain discretization cells, often considered a ‘drawback’ o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db3bf7bb207e63997a81f97ef38ca012
https://doi.org/10.1002/nme.2364
https://doi.org/10.1002/nme.2364
Autor:
S J, Denardo, C M, Richman, D L, Kukis, S, Shen, K R, Lamborn, L A, Miers, L A, Kroger, E A, Perez, G L, Denardo
Publikováno v:
Anticancer research. 18(6A)
Paclitaxel (Taxol) has demonstrated synergistic enhancement of radioimmunotherapy (RIT) of breast cancer with Y-90 labeled antibody ChL6, in the xenografted mouse model. To determine the optimal sequence and timing of RIT and Taxol for a prospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b7334f6f24a3bf59ef7bb4cf0a9baf9b
https://pubmed.ncbi.nlm.nih.gov/9891439
https://pubmed.ncbi.nlm.nih.gov/9891439
Autor:
G L, DeNardo, L A, Kroger, C F, Meares, C M, Richman, Q, Salako, S, Shen, K R, Lamborn, J J, Peterson, L A, Miers, G R, Zhong, S J, DeNardo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(10)
Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and tightly binds 90Y and (111)In was developed. The immunoconjugate, 1,4,7,10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e92eda1ac3f7bc4f2a33263a7c93325c
https://pubmed.ncbi.nlm.nih.gov/9796981
https://pubmed.ncbi.nlm.nih.gov/9796981
Autor:
S J, DeNardo, D L, Kukis, L A, Miers, M D, Winthrop, L A, Kroger, Q, Salako, S, Shen, K R, Lamborn, P H, Gumerlock, C F, Meares, G L, DeNardo
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 39(5)
The novel radioimmunoconjugate, 90Y-DOTA-peptide-chimeric L6 (ChL6), was designed to reduce radiation to critical normal tissues with an exceptionally stable 90Y chelate moiety and a biodegradable linker. Human breast cancer tumors (HBT 3477) in mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4b691977f3ac5f687b8c0286e97d74ca
https://pubmed.ncbi.nlm.nih.gov/9591587
https://pubmed.ncbi.nlm.nih.gov/9591587
Autor:
S J, DeNardo, L A, Kroger, K R, Lamborn, L A, Miers, R T, O'Donnell, D L, Kukis, C M, Richman, G L, DeNardo
Publikováno v:
Cancer. 80
The beneficial effects of radioimmunotherapy (RIT) may result from activation of molecular pathways that lead to programmed cell death (apoptosis). The influences of sequence and timing of 90Y-DOTA-peptide-ChL6 antibody (90Y-ChL6) and anti-epidermal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::186adbc6a531fc0e80ddb79216a0ed23
https://pubmed.ncbi.nlm.nih.gov/9406713
https://pubmed.ncbi.nlm.nih.gov/9406713
Autor:
G L, DeNardo, D L, Kukis, S J, DeNardo, S, Shen, L F, Mausner, R T, O'Donnell, K R, Lamborn, F J, Meyers, S C, Srivastava, L A, Miers
Publikováno v:
Cancer. 80
Lymphomas have been shown to be responsive to 131I immunoconjugates in studies conducted in mice and patients. We have observed that copper 67 (67Cu)-labeled Lym-1 remains in lymphomatous tissue longer than 131I-Lym-1 and, consequently, results in hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8fb67d279c92121e7c112a669641e8d7
https://pubmed.ncbi.nlm.nih.gov/9406712
https://pubmed.ncbi.nlm.nih.gov/9406712
Autor:
G L, DeNardo, D L, Kukis, S, Shen, L F, Mausner, C F, Meares, S C, Srivastava, L A, Miers, S J, DeNardo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(1)
Radioimmunotherapy has shown promising results for treatment of radiosensitive malignancies such as lymphoma. Positive responses have been reported in patients with non-Hodgkin's lymphoma treated with 131I-radiolabeled Lym-1, a mouse anti-lymphoma mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8a82a622abcf85a41286a8b1aeddcf0f
https://pubmed.ncbi.nlm.nih.gov/9815540
https://pubmed.ncbi.nlm.nih.gov/9815540
Autor:
S J, DeNardo, P H, Gumerlock, M D, Winthrop, P C, Mack, S G, Chi, K R, Lamborn, S, Shen, L A, Miers, R W, deVere White, G L, DeNardo
Publikováno v:
Cancer research. 55
Radioimmunotherapy (RIT) in breast cancer patients using I-131-chimeric L6 (ChL6) and in human breast cancer xenografts in nude mice using Y-90-1,4,7,10-tetraazacylododecant N,N',N",N"'-tetraacetic acid-peptide ChL6 (Y-90-ChL6) has shown promise. Tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::712636d34192cd1906ae6a367c75b888
https://pubmed.ncbi.nlm.nih.gov/7493356
https://pubmed.ncbi.nlm.nih.gov/7493356
Publikováno v:
Cancer research. 55(4)
Trial therapy for lymphoma with the radiolabeled chelate-antibody conjugate 67Cu-2IT-BAT-Lym-1 has been promising. It is desirable to deliver therapeutic doses of radiometal using a minimum amount of 2IT-BAT-Lym-1 to minimize the risks of adverse pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7412f44c85e64bb7dc9adf392b03ee5d
https://pubmed.ncbi.nlm.nih.gov/7850803
https://pubmed.ncbi.nlm.nih.gov/7850803
Autor:
G L, DeNardo, L A, Kroger, S J, DeNardo, L A, Miers, Q, Salako, D L, Kukis, I, Fand, S, Shen, O, Renn, C F, Meares
Publikováno v:
Cancer. 73
BrE-3 is monoclonal antibody that has promise for imaging and therapy of human adenocarcinoma. Because of observations in therapeutic trials of yttrium-90 (90Y) escape from radioimmunoconjugates and uptake by the skeleton with resultant bone marrow t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::94b8290faf52f2a291c5ac4d00fce7e9
https://pubmed.ncbi.nlm.nih.gov/8306243
https://pubmed.ncbi.nlm.nih.gov/8306243